Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: A crossover study

Clinical Nephrology

Volumn 72, Issue 4, 2009, Pages 252-258

  Sprague, Stuart M ^a   Ross, E A ^b   Nath, S D ^c   Zhang, P ^d   Pratt, R D ^d   Krause, R ^e  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d SHIRE   (United States)

^e Nephrological Center Moabit   (Germany)

Author keywords

Hyperphosphatemia; Lanthanum carbonate; Phosphate binder; Sevelamer

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; LANTHANUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; SEVELAMER; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOCALCEMIA; INTERSTITIAL NEPHRITIS; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT DISEASE;

EID: 70350359136     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72252     Document Type: Article

References (16)

1. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci. 2007; 96: 2818-2827.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218.
3. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
4. Dacon Report. Intercontinental Medical Statistics; March 2006.
5. Dacon Report. Intercontinental Medical Statistics; June 2009.
6. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3: 1423-1429.
7. Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ. A randomized, double-blind, crossover design study of sevelamer hy drochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007; 68: 386-391.
8. FOSRENOL Prescribing Information. Shire Pharmaceuticals, Wayne, PA, USA; 2008.
9. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Trans plant. 2000; 15: 1014-1021.
10. Hutchison AJ. Improving phosphate-binder therapy as a way forward. Nephrol Dial Trans plant. 2004; 19 Suppl 1: i19-i24.
11. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005; 100: c8-c19.
12. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA, SPD405-309 Lanthanum Study Group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008; 110: c15-c23.
13. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009; 20: 388-396.
14. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Trans plant. 2003; 18: 1731-1740.
15. Renagel Prescribing Information. Genzyme Therapeutics, Cambridge, MA, USA; 2008.
16. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-1187.